The India infertility gonadotropins market is estimated to be valued at USD 273.0 Mn in 2026 and is expected to reach USD 512.9 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 13.3% from 2026 to 2033. Infertility gonadotropins form an essential component segment of India’s fast-growing assisted reproductive technology (ART), owing to the increasing number of couples facing fertility issues in India. FSH, LH, and chorionic gonadotropin are examples of gonadotropins that help in regulating the functions of the ovaries, which is useful during fertility treatments, particularly IVF. Recombinant forms of such medications are generally recommended as they offer high purity.
There are several factors responsible for driving the growth rate of the market for infertility gonadotropins in India. These factors include increased awareness about reproductive issues, delayed marriages, infertility due to unhealthy lifestyles, and improved acceptance rates regarding fertility treatments. In addition, some other factors are disposable incomes, urbanization, proliferation of fertility centers in tier-I and tier-II cities, and medical advancements.
Market Dynamics
India infertility gonadotropins market is mainly driven by an increase in the number of infertility cases due to late parenthood, changes in lifestyle habits, and reproductive problems arising due to stress. Rising prevalence of assisted reproductive technology and reduced social taboos related to fertility have led to an increasing patient base. Also, the development of advanced technologies used in fertility treatments has played a key role in improving the success rates of IVF treatment.
The market faces some restraints, such as high cost of treatment, minimal or no reimbursement for the cost, high costs involved for medium and lower middle-class patients, adherence to standards, storage issues, among others. The opportunities in this market can arise through expanded availability of fertility clinics in semi-urban locations, increased medical tourism, fertility preservation, biologics and biosimilar drugs, and telemedicine services.
Key Features of the Study
• This report provides in-depth analysis of the India infertility gonadotropins market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the India infertility gonadotropins market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Merck KGaA, Ferring Pharmaceuticals, Organon & Co., IBSA Institut Biochimique SA, Bharat Serums and Vaccines Limited, Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Lupin Limited, and Dr. Reddy's Laboratories Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The India infertility gonadotropins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the India infertility gonadotropins market
Market Segmentation
• Type Insights (Revenue, USD Mn, 2021 - 2033)
o Human Chorionic Gonadotropin (hCG)
o Follicle Stimulating Hormone (FSH)
o Menotropins (hMG)
o Others
• Product Type Insights (Revenue, USD Mn, 2021 - 2033)
o Branded
o Generics
• Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
o Intramuscular
o Subcutaneous
• Application Insights (Revenue, USD Mn, 2021 - 2033)
o Female Infertility
o Male Infertility
• Type of Infertility Insights (Revenue, USD Mn, 2021 - 2033)
o Primary Infertility
o Secondary Infertility
• Age Group Insights (Revenue, USD Mn, 2021 - 2033)
o 18–25
o 26–30
o 31–35
o 36 and Above
• Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Government Supply / Public Health Programs
• Key Players Insights
o Merck KGaA
o Ferring Pharmaceuticals
o Organon & Co.
o IBSA Institut Biochimique SA
o Bharat Serums and Vaccines Limited
o Intas Pharmaceuticals Ltd.
o Sun Pharmaceutical Industries Ltd.
o Zydus Lifesciences Ltd.
o Lupin Limited
o Reddy's Laboratories Ltd.

Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
 Market Definition and Scope
o Executive Summary
 India Infertility Gonadotropins Market, By Type
 India Infertility Gonadotropins Market, By Product Type
 India Infertility Gonadotropins Market, By Route of Administration
 India Infertility Gonadotropins Market, By Application
 India Infertility Gonadotropins Market, By Type of Infertility
 India Infertility Gonadotropins Market, By Age Group
 India Infertility Gonadotropins Market, By Distribution Channel
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Impact Analysis
o Key Highlights
o Regulatory Scenario
o Product Launches/Approvals
o PEST Analysis
o PORTER’s Analysis
o Market Opportunities
o Regulatory Scenario
o Key Developments
o Industry Trends
4. India Infertility Gonadotropins Market, By Type, 2021-2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 - 2033
 Segment Trends
o Human Chorionic Gonadotropin (hCG)
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Follicle Stimulating Hormone (FSH)
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Menotropins (hMG)
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. India Infertility Gonadotropins Market, By Product Type, 2021-2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 - 2033
 Segment Trends
o Branded
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Generics
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. India Infertility Gonadotropins Market, By Route of Administration, 2021-2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 - 2033
 Segment Trends
o Intramuscular
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Subcutaneous
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. India Infertility Gonadotropins Market, By Application, 2021-2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 - 2033
 Segment Trends
o Female Infertility
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Male Infertility
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. India Infertility Gonadotropins Market, By Type of Infertility, 2021-2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 - 2033
 Segment Trends
o Primary Infertility
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Secondary Infertility
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
9. India Infertility Gonadotropins Market, By Age Group, 2021-2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 - 2033
 Segment Trends
o 18-25
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o 26-30
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o 31-35
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o 36 and Above
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
10. India Infertility Gonadotropins Market, By Distribution Channel, 2021-2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 - 2033
 Segment Trends
o Hospital Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Retail Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Online Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Government Supply / Public Health Programs
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
11. Competitive Landscape
o Merck KGaA
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Ferring Pharmaceuticals
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Organon & Co.
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o IBSA Institut Biochimique SA
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Bharat Serums and Vaccines Limited
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Intas Pharmaceuticals Ltd.
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Sun Pharmaceutical Industries Ltd.
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Zydus Lifesciences Ltd.
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Lupin Limited
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Reddy's Laboratories Ltd.
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
12. Analyst Recommendations
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
13. References and Research Methodology
o References
o Research Methodology
o About us
*Browse 32 market data tables and 28 figures on ‘Infertility Gonadotropins Market – India forecast to 2033